Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund report, recording an average monthly valuation of $741,435,710 despite a challenging month across digital asset markets. The fund
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group
Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (“EBC”) has been named Best Broker for
Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care
LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live, invest, and secure residence or citizenship
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma
